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A B S T R A C T
Diffuse pulmonary metastasis secondary to primary peritoneal malignant mesothelioma is rarely reported in the
literature. In this report we describe a 59-year-old Caucasian women with no known previous asbestos exposure
presenting with bilateral diffuse pulmonary opacities in association with primary malignant peritoneal me-
sothelioma. The diagnosis was confirmed by ultrasound guided abdominal and bronchoscopy, trans-bronchial
lung biopsy. The biopsy demonstrated positive staining with AE1/3, CK7, CK5/6, WT1, calretinin and D2 40.
The cells were negative for BerEP4, PAX8, CA125, ER, CD34, ERG, P63, P40, Melan A, Gata3 and mammaglobin.
The morphology and immunohistochemical profile supported a diagnosis of epithelioid malignant mesothe-
lioma.
1. Introduction
Pleural malignant mesothelioma is known to be strongly associated
with asbestos exposure in 80% of cases, followed by the peritoneum as
the second most common primary site [1]. Diffuse pulmonary in-
volvement secondary to primary peritoneal mesothelioma is rarely re-
ported in the literature [2]. In this report we describe a patient with no
known asbestos exposure presenting with bilateral pulmonary opacities
in association with primary malignant peritoneal mesothelioma, which
was diagnosed by bronchoscopy, trans-bronchial lung biopsy.
2. Case
A 59-year-old Caucasian woman presented with non-specific ab-
dominal discomfort. Clinical examination revealed a palpable abdom-
inal mass. There was no other abdominal symptoms of significance or
unintentional weight loss nor constitutional symptoms. She had no
significant past medical history and was not on any regular medica-
tions. She was a current smoker with a 30-pack year history. She had no
known occupational or environmental exposure to asbestos.
Computed tomography (CT) of the abdomen demonstrated ex-
tensive peritoneal omental caking with infiltration to the anterior
Fig. 1. CT Abdomen demonstrating omental caking with an infiltrative mass
into the right anterior abdominal wall.
https://doi.org/10.1016/j.rmcr.2019.03.003
Received 14 January 2019; Received in revised form 3 March 2019; Accepted 3 March 2019
∗ Corresponding author. Department of Respiratory Medicine, Royal Darwin Hospital, Darwin, NT, Australia.
E-mail address: subash.heraganahally@nt.gov.au (S.S. Heraganahally).
Respiratory Medicine Case Reports 26 (2019) 326–327
2213-0071/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
abdominal wall (Fig. 1). Ultrasound-guided biopsy of the abdominal
mass revealed large, pleomorphic epithelioid cells, within fibrous
stroma. These cells stained positively with AE1/3, CK7, CK5/6, WT1,
calretinin and D2 40. The cells were negative for BerEP4, PAX8, CA125,
ER, CD34, ERG, P63, P40, Melan A, Gata3 and mammaglobin. The
morphology and immunohistochemical profile supported a diagnosis of
epithelioid malignant mesothelioma. (figure –2a).
The patient subsequently presented with exertional dyspnoea. A CT
scan of chest revealed moderate right sided pleural effusion, bilateral
hilar and mediastinal lymphadenopathy, extensive bilateral pulmonary
parenchymal & interstitial opacity along with interlobular septal
thickening, suggestive of lymphangitic spread. (Fig. 3). A bone scan and
a Brain CT were negative for distant metastases. Pleural fluid ex-
amination showed it was an exudative effusion, cytological examina-
tion was inconclusive. Bacterial cultures and acid fast bacilli were ne-
gative.
In order to obtain a definitive diagnosis of the pulmonary infiltrates,
she underwent a bronchoscopy with trans-bronchial lung biopsy
(TBLB). Bronchial washing and lavage did not reveal malignant cells
and was negative for microbial or fungal elements. The TBLB confirmed
pulmonary epithelioid malignant mesothelioma, demonstrating lung
tissue with infiltrating cells, similar to that of initial peritoneal biopsy,
also stained positively with CK7, calretinin, WT1 and D2 40. They were
negative for Napsin A, TTF1 and P40 confirming pulmonary metastatic
malignant epithelioid mesothelioma (Fig. 2b). The TBLB biopsy samples
were small and did not contain muscle/fat tissue, hence no invasion
into muscle/fat were demonstrated. Lymphovascular invasion was not
seen either. Although TBL biopsy did not did not demonstrate lym-
phangitic invasion, however, the CT scan findings were highly sug-
gestive of lymphangitic spread. Unfortunately the patient had an ag-
gressive course of disease and died within three months of initial
presentation, prior to the initiation of any systemic treatment.
3. Discussion
We describe a rare presentation of diffuse pulmonary infiltrates
secondary to malignant peritoneal mesothelioma. To the best of our
knowledge, there are only occasional reports of similar cases described
in the literature [2]. This case is presented to highlight that mesothe-
lioma should be considered in the list of differential diagnosis in pa-
tients presenting with diffuse pulmonary infiltrates in relevant clinical
context.
The patho-physiology of pulmonary parenchymal involvement sec-
ondary to peritoneal mesothelioma is thought to be related to haema-
togenous metastasis or by diffuse retrograde permeation and emboli-
zation of the lymphatic system [3]. Bronchoscopy and TBLB procedure
can be considered for early definite diagnosis, especially when the
primary site is obscure [4]. Moreover, Malignant mesothelioma re-
gardless of site carries a poor prognosis, with a median survival of
approximately 12 months from diagnosis, even when treated with
modern combination chemotherapy [5]. More recently ALK (Anaplastic
lymphoma kinase) testing has been shown to be useful in patients with
peritoneal mesothelioma [6], however this test is not yet routinely
performed in our centre. We believe this case will prompt other re-
searchers to publish similar reports and develop guidelines for early
diagnostic and management strategies.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.rmcr.2019.03.003.
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Fig. 2. a & b: Peritoneal biopsy showing malignant mesothelioma (2a) and Trans-bronchial lung biopsy showing pulmonary malignant mesothelioma (2b).
Fig. 3. CT chest demonstrating bilateral diffuse interstitial opacity and inter-
lobular septal thickening along with the right side pleural effusion.
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